Larimar Therapeutics, Inc.

Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using a cell penetrating peptide technology platform. The company is headquartered in Bala Cynwyd, Pennsylvania, and operates with approximately 65 full-time employees. Its lead product candidate, CTI-1601, is currently in Phase 2 open-label extension clinical trials for Friedreich's ataxia, a rare, progressive, and fatal inherited neurological disorder characterized by progressive loss of coordination and muscle weakness.

The company's pipeline focuses on leveraging its proprietary peptide platform to address unmet medical needs in rare diseases. CTI-1601 represents the primary clinical development focus, with the ongoing trial designed to evaluate safety, tolerability, and efficacy in patients with Friedreich's ataxia. As a clinical-stage entity, Larimar does not currently generate product revenues and remains dependent on capital financing to fund operations and research activities.

The company operates as a publicly traded entity on the Nasdaq exchange, incorporated in Delaware, with a market capitalization of approximately $0.3 billion. Larimar's business model centers on advancing its single lead candidate through clinical development toward potential regulatory approval and commercialization, typical of biotechnology firms in early-to-mid stage clinical development.